VCBeat Health Contact Us
Home Sanofi Acquires Vigil Neuroscience for $470 Million to Add Oral TREM2 Agonist VG-3927 to Neurology Pipeline

Sanofi Acquires Vigil Neuroscience for $470 Million to Add Oral TREM2 Agonist VG-3927 to Neurology Pipeline

May 22, 2025 15:24 CST Updated 15:24
Vigil Neuroscience

Neurodegenerative Disease Treatment New Drug Developer

Sanofi

Pharmaceutical R&D Developer

Image
Local time on May 22, Sanofi announced that it had reached an agreement to acquireVigil Neuroscience, Inc., obtaining the latter's product for treatmentAlzheimer's Disease（AD）Oral small moleculeVG-3927（Vigil Neuroscience's Second Molecular ProjectVGL101 was not acquired.), this acquisition will enhance Sanofi's presence inNeurology FieldThe early R&D pipeline.
Image
Screenshot source: Corporate official website
According to the terms of the agreement, Sanofi will acquire all outstanding common shares of Vigil Neuroscience, Inc. for $8 per share in cash at the closing of the transaction, with an equity value of approximately$470 million(Calculated after complete dilution).
In addition, Vigil's shareholders will receive non-transferable contingent value rights for each share of Vigil stock. (CVR), which will entitle the holder to a $2 deferred cash payment upon the first commercial sale of VG-3927.
It is worth mentioning that this is not the first collaboration between the two companies. In June 2024, Sanofi had previously collaborated with...Vigil Neuroscience Conducts$40 millionThe strategic investment includes the exclusive right to prioritize negotiations for the research, development, production, and commercialization exclusive license, grant, or transfer of VG-3927.
VG-3927 is aSpeciesOral Small Molecule TREM2 Agonist, activating TREM2 is expected to enhance the neuroprotective function of microglia in Alzheimer's disease. This drug has currently completed a Phase I clinical trial.（NCT06343636）。
InAt the 2025 AD/PD International Conference,Vigil Neuroscience, Inc. announced positive results of the trial in an oral presentation. The data showed:

  • VG-3927 Exhibits Predictable and Dose-Dependent Pharmacokinetics (PK) Features, SupportOnce daily dosing. At the same time, VG-3927 has high central nervous system permeability.

  • The PK and sTREM2 reduction observed in the single-dose AD cohort were consistent with those in healthy volunteers, as well as across different genotypes of AD patients.（TREM2 andApoE Gene Variation)ChinasTREM2 ReductionAre similar.

  • At a dose of 25 mg, VG-3927 achieved levels in the cerebrospinal fluidThe maximum reduction in sTREM2 was approximately 50%.。

  • PK/PD data support the selection in Phase II trials for AD patients25 mg once daily oral dose。

  • VG-3927 in all populations(Healthy volunteers, elderly participants, AD patients)Both exhibited good safety and tolerability, with no serious adverse events occurring.

  • All treatment-related adverse events（AE）All were mild or moderate and resolved on their own.

Cover source: ZCOOL Hailo
Disclaimer:This article is for information sharing only, and does not represent the position or viewpoint of Insight. It does not recommend or introduce any treatment options. If necessary, please consult and contact正规医疗机构.

Editor：ccai
PR Article Coordination: WeChat insightxb
SubmissionWeChat: insightxb; Email: insight@dxy.cn


图片
Diversified functions, traceable data……
Insight Database Web Version Awaits Your Experience图片
Click to read the original text,ImmediatelyUnlock！图片图片